RU58841 is an experimental, non‑steroidal anti‑androgen drug originally developed in the 1980s by the French pharmaceutical company Roussel Uclaf. It was investigated as a topical treatment for androgen‑dependent skin conditions such as acne, androgenetic alopecia (male pattern baldness), and hirsutism.
Mechanism of Action
RU58841 works differently from the more common hair‑loss drug finasteride:
●Different target: RU58841 is an androgen receptor antagonist. It binds to androgen receptors on hair follicle cells, occupying the binding site and directly blocking dihydrotestosterone (DHT) and other androgens from attaching to the receptor. In contrast, finasteride reduces DHT production by inhibiting the enzyme 5‑alpha‑reductase.
●Different systemic impact: Because it acts at the receptor level, RU58841 does not interfere with the body's own hormone production. In theory, it has less impact on systemic hormone levels. Finasteride, however, does affect systemic hormone levels.
Research Status and Efficacy
●Effective in animal studies: In a study on stump‑tailed macaques (an animal model for androgenetic alopecia), topical application of RU58841 significantly increased hair density, thickness, and length, with no detectable systemic side effects.
●Lack of human clinical data: Despite promising animal results, RU58841 has never completed large‑scale human clinical trials. Therefore, robust data on its long‑term efficacy and safety in humans are severely lacking.
https://www.hormonerawsource.com/raw-steroid-powders/top-quality-ru58841-powder-treatment-of.html
